Public health strategies for cancer control are determined by the epidemiological, clinical and biological characteristic of each cancer. Primary prevention is most easily implemented in cancers due to one or few factors. Secondary prevention is best suited for frequent cancers with a long preclinical, detectable phase. Therapy has to be relied upon in rare cancers of unknown etiology. A critical evaluation of the accomplishments ofthese three approaches shows that the potential role in cancer control ofearly detection and treatment is severely hampered by the high social and human costs, that are only partially counterbalanced by the limited effectiveness. As a consequence, primary prevention should be regarded as the key approach to cancer control, and efforts should be concentrated on studies concerning cancer etiology and on the implementation of preventive measures.
INTRODUCTION
Cancer in Western countries is responsible for more than 20% of all deaths and ranks second only to heart disease as the leading cause of death. Between 300 and 400 new cases are diagnosed every year for every 100,000 people, and many of those who are not killed within a few years by the disease will suffer permanent scars, mutilations, psychological consequences, increased risk of second cancers, and the toxic effects of the various treatments. As a consequence, it is clear that cancer control should represent a public health priority. Yet, in devising public health strategies, the feasibility, potential benefits, costs, and risks of every available approach must be carefully evaluated in order to avoid useless or even harmful efforts and to select the most costeffective strategies. IN WESTERN COUNTRIES It has been estimated (32) that in 1985, excluding in sitir carcinomas'and non-melanoma skin cancers, more than 900,000 new cancer cases will occur in the U.S. In the U.S., among males, lung cancer is the most frequent cancer (220/0, followed by prostate * Presented at the Third Sardinian International Symposium, October 6-9, 1985 in Cagliari, Italy. cancer (1 9%>, and colorectal cancer (1 5%). Among females, breast cancer accounts for 26% of all new cases, followed by colorectal cancer (1 6%>, and cancers of the uterus (1 1Yo).
DISTRIBUTION OF CANCER
Looking at mortality data, in 1981 cancer in the U.S. was the cause in death certificates from more than 420,000 cases, accounting for 21% ofall deaths.
Approximately 35% of cancer deaths in males are currently attributed to lung cancer, which is followed by colorectal cancer (12%), and prostate cancer (10%). Among females, it is expected that in 1985 breast cancer and lung cancer will cause a similar number of deaths, accounting each for 18% of the total cancer deaths, followed by colorectal cancer, which will account for 15% of the cancer deaths.
Time trends in cancer incidence and mortality have been argued upon quite considerably in recent years (9,12), as changes in diagnostic accuracy, staging procedures, certification, registration, and treatment make it extremely difficult to compare rates in different periods of time. Furthermore, various sets of data of different completeness, quality, and reliability are available to this purpose. However, it is clear that three major features have dominated time trends in cancer mortality during the last decades in Western countries (32) :
1) The dramatic and steady decrease in mortality from stomach cancer, which used to be the most lethal cancer. Due to the commonly poor prognosis 213 214 SANTI ET AL TOXICOLOGIC PATHOLOGY of this disease, this decrease undoubtedly reflects a true decrease in incidence. The causes of such decrease have not yet been clearly established, even though dietary factors are likely to be involved.
2) A steady decrease in death rates from uterine cancer, which are mainly related to the decrease in mortality from cervical cancer. In several countries, this decrease was apparent before screening became widespread. It is therefore difficult to separate the different contributions to this decline from early detection programs and from other unknown preventive factors.
3) The dramatic increase in mortality from respiratory cancers, which has been attributed m.ainly to the adoption of cigarette smoking during this century and to occupational exposures to carcinogenic substances. The relevance of these two factors in the present "epidemic" of lung cancer is so large that any possible role of other factors such as environmental pollution, is difficult to evaluate. Smoking accounts for more than 80% of the respiratory cancers, even though interacting occupational factors, either new or old ones, significantly contribute to these figures (1 5).
With regard to the remaining most common cancers, the death r a t e s h the U.S. have not shown major variations in the last 30 years, when death certification is believed to have become quite reliable. This finding may reflect a stable incidence, or an increasing incidence balanced by a more effective or timely treatment. The latter is clearly the case in Hodgkin's disease, and in many types of leukemias, where a decreasing trend in mortality has recently been observed. Unlike Doll and Pet0 (9), we believe that the stable death rates from breast and colorectal cancer may well conceal an increasing incidence, as suggested by Cancer Registries Cancer Surveys data (36, 39). Although surgical treatment in breast and colorectal cancer has not changed in the last 30 years, the early diagnosis of these cancers on the average appears to have increased in frequency, possibly resulting in higher cure rates.
Time trends in cancer incidence are even less reliably assessed as changes occur in cancer registration procedures and in diagnostic accuracy. However, available data confirm the decrease in stomach cancer incidence, and the increase in lung cancer. An increasing trend in incidence is suggested also for cancers of many other sites, such as endometrium, breast, colon and rectum, melanoma, pancreas, and others (36, 39).
APPROACHES TO CANCER CONTROL
The distinction in primary prevention, early detection, and therapy is not clear cut, since there are several types of interventions which do not easily fit into any of these three categories (e.g., chemoprevention). However, the term "primary prevention'' encompasses all activities aimed at preventing or reducing exposures or conditions that increase cancer risk. Early detection (often referred to as secondary prevention), includes the interventions aimed to diagnose and treat cancer (or precancerous lesions) before symptoms occur, while therapy is usually administered after the patient has shown clinical symptoms of cancer.
Each of these approaches is best suitable to cancer control under specific circumstances. Primary prevention obviously requires knowledge of the etiologic factors or, at least, of the conditions which increase cancer risk. This knowledge, and the possibility of preventing exposure to the responsible factors, are more likely to occur when a cancer is specifically related to a single agent, or when a carcinogenic exposure occurs in particular conditions, such as at the workplace, or because of medical treatment.
Early detection programs must face high costs and the need to administer diagnostic tests, which sometimes involve risk or discomfort, to healthy populations. Furthermore, false-positive results sometimes lead to unnecessary confirmatory tests or even to harmful treatments. In many cancers preclinical diagnosis is not possible, or only at a stage of the disease when it can no longer be possible to modify its natural course, As a consequence, secondary prevention is an acceptable public health strategy only for high incidence cancers (or when it is possible to identify high risk groups) with a long asymptomatic phase when the disease is localized, can be diagnosed with tests which involve little discomfort to the patient, and are not too expensive.
Therapy, of course, is the best choice for cancers which can be treated effectively after symptoms have occurred. It is also the only choice for cancers of unknown etiology, which are too rare to make early diagnosis programs cost-and risk-effective.
As we have seen, primary prevention, early detection, and therapy are somehow complementary in nature. Primary prevention is most suitable for cancers due to one or few agents under well-defined exposure conditions, early detection can be considered for common cancers related to many agents which are widespread and/or poorly known, while therapy has to be relied upon dealing with rare cancers of unknown etiology.
Unfortunately, a large proportion of the cancer burden in Western countries is due to cancers which do not fit any ofthe above mentioned features. These are frequent cancers, of unknown etiology, or associated to factors not amenable to prevention, and can seldom be diagnosed at a sufficiently early stage.
Therapeutic attempts, in these instances, do not reflect a public health choice, but rather the inadequacy of our knowledge.
PRESENT SITUATION AND PERSPECTIVES IN CANCER CONTROL A) Therapy
Treatment has a widely different role in the control of the various cancers, depending on their frequency and natural history.
Accordingly, we can identify three groups of cancers:
1) Cancers where effective and safe treatment is already available, provided that symptoms . are quickly reported to an alerted physician: this is the case of non-melanoma skin cancers, where presently the cure rate is higher than 90% (29) . Cancer of the lip, and, to a lesser extent of the tongue, are very often cured, too, but frequently with disfiguring or disturbing scars.
2) Non-epithelial cancers of unknown etiology, which are too rare to make early detection programs cost-effective and risk-effective. Most of these cancers do not show up in clusters, nor have they been found to be associated with specific risk factors in the few epidemiological studies which, due to their rarity, have been carried out. Hence, regarding these cancers, efforts have to be directed toward treatment, and good results have often been achieved by means of chemo-and/or radiotherapy. Rare cancers for which effective treatment is presently available with high rates of long-term remission and/or cure, include many childhood leukemias and solid tumors, Hodgkin's disease, testicular cancer, and, with less satisfactory results, non-Hodgkin's lymphomas, adult leukemias and other even rarer cancers (1 6).
3) Frequent cancers which are not amenable to prevention because their causes are still unknown, or because effective preventive measures have not yet been implemented despite the availability of sufficient knowledge: in many of these cancers, which are mainly solid epithelial tumors, treatment appears of some use, and improvements in survival rates have been reported in the last decades, but it is difficult to assess the extent of any improvement in the prognosis of these cancers over recent years. Due to the widespread use of refined diagnostic tools, many lumps are detected that are histologically classified as cancer, even if they may have a benign biological behavior (14). Furthermore, even if the available treatment for a given cancer is not effective at all, an earlier diagnosis and treatment may apparently result in prolonged survival. Limiting the comparison to stage-specific survival rates at different times does not help assessing treatment emcacy. Because of more accurate staging procedures today, patients assigned to a stage of the disease tend, on the average, to have less advanced disease. As a consequence, they have a better prognosis than patients diagnosed as being in the same stage in the past, independently of therapeutic improvements (1 3).
In an unknown but relevant proportion of many of these types of cancer, the therapeutic efforts do exert positive effects (again behind that of palliation), which may range from prolongation of the "disease-free" interval to cure. These cancers include oral and laryngeal cancers, breast cancer, uterine and ovarian cancers, colorectal cancer, bladder and prostate cancers, and skin melanomata (6).
However, even in this group of cancers, available treatments are far from satisfactory. Case-fatality rates are still high for many of these, and cures are possible only by means ofaggressive treatments when the disease is localized at the time it is detected. Only therapies of limited efficacy are available when the disease is no longer localized or in the case of recurrences. Major improvements in the prognosis of these patients are not to be expected in the near future in light of the therapeutic approaches which have recently been recognized as effective or which are currently clinically tested (7, 11, 26). Furthermore, due to their frequency and to the cost of the various treatments, these cancers also represent a relevant financial burden for the health systems.
Finally, in several cancers belonging to this group, therapy is of little or no use. Esophageal cancer, liver cancer, and pancreatic cancer are almost invariably and rapidly fatal. A very small proportion of the cases of stomach and lung cancer, which are fortuitously discovered at a very early stage, are cured by surgery. The prognosis in almost all other cases is poor, and, so far, no treatment has been proved to be effective (6).
The majority of the most common cancers have case-fatality rates that range from more than 25% to almost 100% (6, 32) . Many of the heroic efforts to treat advanced or recurrent cases are probably of little use in most instances, and are so aggressive as to raise serious questions of medical ethics.
B) Early Detection
Screening for cancer is extremely costly and involves risks and discomfort to otherwise healthy individuals. Unless reduction in mortality from this disease is demonstrated by appropriately designed studies, it cannot be recommended as a measure of public health policy (22) .
Reduction in mortality has been shown to be associated with periodic screening for breast cancer (3 l), and with less conclusive evidence for cervical cancer (4). On the other hand, efficacy of early de-216 SANTI ET AL TOXICOLOGIC PATHOLOGY tection programs has not been complete in both sites (22, 27) . The inadequacy ofavailable screening tests, the unsatisfactory degree of compliance on the part of patients, as well as financial and organizational problems greatly limit the potential impact of screening programs for these two cancers. However, some results might have been already achieved: the causes for the decrease in cervical cancer mortality in Western countries are not established, but it appears that early diagnosis has significantly contributed to the reduction of mortality (5, 18) . Breast cancer mortality has not increased in the last 5 to 10 years in Western countries, despite an apparently increased incidence. This discrepancy between trends in incidence and in mortality may be due to the earlier diagnosis of breast cancer as a consequence of the increased awareness of both physicians and the general population. Among other sites early diagnosis in colorectal cancer is possible. This cancer occurs in most instances on preexisting lesions; polyps can be diagnosed and removed before they become invasive cancers. The available evidence concerning the efficacy of screening programs by means of fecal blood tests is not conclusive and there is no quantitative estimate ofthe potential reduction in mortality that could be attained with the implementation of such programs. False-positive individuals, which are inescapable in screening programs, and not uncommon with fecal blood tests, have to undergo subsequent costly unpleasant diagnostic procedures. Presently, the question of whether or not asymptomatic individuals in the general population should undergo periodic fecal occult blood tests remains open (33) .
The possible implementation of screening programs has been evaluated for cancers of three other sites, namely lung, bladder, and oral cavity. The conclusion has been that for none of these sites screening can be recommended (27) :Cancers of other sites fall in either one or both of the following two groups: 1) they are too rare to make early detection programs convenient from a cost-benefit and risk-effectiveness viewpoint, or 2) no tests of adequate diagnostic accuracy, which can be used on a large scale, are available for the diagnosis at a sufficiently early stage.
In conclusion, it appears that early diagnosis programs on asymptomatic populations are not likely to produce dramatic changes in the overall pattern of cancer mortality, besides the benefits already obtained and those which may be obtained in breast and cervical cancers, and perhaps colorectal cancer.
In a more general perspective, relying on early detection of many cancers would imply acceptance of the fact that most individuals will have to live in the constant fear of developing cancer, and to undergo periodic, often unpleasant examinations. A substantial proportion of these individuals in the U.S., as high as 9% of women for breast cancer, or 6% of both sexes for colorectal cancer (30), will develop a cancer in their lifetime, and will have to undergo often mutilating treatments (e.g., mastectomy).
This conclusion refers only to active interventions on asymptomatic and healthy populations, and does not involve any judgment concerning the need that patients with cancer symptoms be promptly referred to a physician for diagnosis and treatment. However, many of the early symptoms of common cancers are so frequent and aspecific that this distinction is not always clear cut.
C) Pt-iiirary Prewiitioii
The overall cancer incidence in Western countries represents the consequence of exposures of various durations and intensities to a variety of factors experienced by individuals throughout their lives. As a consequence, any attribution of risk should not be based on the present types and levels of exposures but should rely on estimates of previous exposures, often impossible to identify on an individual basis. However, it is possible to make assumptions and extrapolations.
In this regard, the most important point is that huge differences in cancer onset rates are observed between and within countries. These differences are particularly large for cancers that are common in some parts of the world. Practically, no paticular type of cancer shows a uniformly high incidence throughout the world (24) . Both geographical comparisons and migrant studies have ruled out the possibility that this variation in cancer incidence is due to genetic factors, at least not to a large extent (19, 36) .
Differences in cancer incidence between countries must be underestimates of the true overall impact of the environment on cancer risk, since in low risk areas some people have lifestyles and exposures resembling those of people living in high risk areas, and vice versa. Nevertheless, these differences are often larger than those observed when, within a country, we compare the risk of individuals having a risk factor with those not having it. Differences in cancer registration can only in part explain this fact. For instance, family history of colorectal cancer (the strongest established risk factor for colon cancer) increases the risk by a factor of 3, while the incidence in U.S. is 10 times that reported in lowrisk countries (36) . If we could modify the most important known risk factors for breast cancer, we could at best halve breast cancer incidence in the U. while the incidence in Connecticut is 6 times higher than that observed among nonJews in Israel (36) . Even in lung cancer, with recognized determinants such as cigarette smoking and occupation, it is difficult to explain the greater than 30-fold difference in incidence between U.S. and Nigerian males. There are some exceptions in several rare hereditary cancers.
The implications of this observation are clear. Our knowledge of the determinants of cancer in Western populations is grossly inadequate when compared to the evidence derived from geographical comparisons. This inadequacy stems from the intrinsic and unavoidable drawbacks of epidemiological studies, which, due to their observational nature, are research tools of limited sensitivity and specificity (23) . This fact undermines the potential role of epidemiological studies in unraveling cancer etiological factors that are amenable to prevention.
Even though many other factors are specifically relevant to the etiology of the various cancers, patterns in cancer incidence and mortality seem to be largely determined in Western countries by three factors that are identified: diet, cigarette smoking, and Occupation.
Diet. This factor haS been most often suggested as being responsible for a large proportion of the geographic variation in cancer incidence and mortality (2). For many cancers, analytical studies in a country, mainly of the case-control type, suggest trends that are roughly in agreement with those indicated by ecological comparisons, correlating with the average per capita consumption ofvarious items or nutrients. Furthermore, animal studies have shown that dietary manipulations can produce many-fold differences in cancer incidence (37, 38) . Cancers that are common in the West and in which diet is thought to play a relevant role include stomach, colon, breast, endometrial and prostate cancers. In these cancers, risk appears related to the dietary pattern, rather than to one or a few specific dietary components. In many other cancers, a potential role (either carcinogenic or protective) of various dietary items or micronutrients, such as vitamins, has been suggested (1 7).
The overall potential role of diet in cancer prevention is undoubtedly very important. Projections of the proportion of cancer deaths which could be avoided by means ofmodifications ofdietary habits, once sufficient evidence has been obtained, range from 10% to 70% (9). However, at the moment, documented evidence shows that little can be clone, and it is highly unlikely that the answer will be provided by epidemiological studies of the observational type currently being carried out. Diet is probably the most difficult subject to study in epidemiology, and, within a given country, most individuals share a diet which is too similar for trends to become evident. As a consequence (17), we either will have to rely more heavily on evidence derived from animal studies specifically designed to test hypotheses that have arisen from epidemiological observations, or, we will have to design and carry out clinical trials aimed at testing those hypotheses on humans. The latter option can be extremely expensive and it would require follow-up periods of decades, probably leading to uncertain or not applicable results unless new, innovative studies are devised (37) .
Available evidence has not been considered sufficient to allow public health guidelines to be implemented, and only general suggestions have been forwarded (25) . These suggestions include reduced intake of salt, alcohol, fat (saturated and unsaturated), and preserved foods, accompanied by increased consumption ofhigh fiber foods, fresh fruits, and vegetables as well as reduced contamination of foods with known or potential carcinogens. Many other factors can be related to cancer risk, and therefore deserve careful investigation (1). It is noteworthy that the type of diet that appears to be the best method for preventing many types of cancers is singularly similar to the diet that some anthropologists believe has been typical of mankind during the evolution from a few million years to some thousands ofyears ago (10). Even more interesting from a public health viewpoint, this type of diet is likely to be effective in preventing a number of cardiovascular diseases.
Tobacco. Cigarette smoking is the single, most important, firmly established determinant of mortality due to cancer in Western countries. Various estimates of the proportion of cancer deaths that could be prevented by removing cigarette smoking from our society range from 20% to 40% (9). Firmly associated with cigarette smoking include cancers of the oral cavity, larynx, esophagus, lung, kidney, bladder, and, with less conclusive evidence, the pancreas. The proportion of preventable deaths for each of these sites ranges from about 25% for kidney cancer to more than 70%, and probably 80% for lung cancer. The risk of smoking does not only lie in its carcinogenic potency, but also in the interaction with other agents, such as alcohol, asbestos, and radiations, usually with synergistic effects.
The possibility of modifying smoking habits in the general population has long been questioned, and it is becoming increasingly clear that it is possible to prevent people from taking up smoking, and in some societies smoking is no longer considered socially acceptable. Thus, even though strong regulations have not been implemented, the proportion 218 SANTI ET AL TOXICOLOGIC PATHOLOGY of smokers among U.S. males is decreasing (35) . It appears that smokers who quit, experience within a few years an appreciable reduction in lung cancer risk as compared to smokers who don't. For other cancers, and particularly for bladder cancer (2Q the increased risk might last longer, since smoking might act through different mechanisms.
Smoking control should represent a public health priority because of its impact on cancer and other diseases. It must be stressed that most tobacco-related cancers have poor prognosis, and are not suitable to early diagnosis programs.
Occupation. The demonstration of the role of occupational factors in cancer etiology has been one of the most successful accomplishments of epidemiology in recent years. The cooperation of scientists working in epidemiology and chemical carcinogenesis made it possible to identify and prevent many hazardous occupational exposures. Furthermore, the demonstration of increased cancer incidence as a result of occupational exposure to various agents has resulted in two advantages: 1) The need for testing potential carcinogenicity of substances before allowing human exposure has been widely recognized, and to this end techniques were developed, regulations adopted, 'and monitoring systems implemented. 2) It has been possible to assess the potential hazard of exposure of the general population to low levels of chemicals where effects had been recognized only in high level workplace exposure conditions.
Prevention of occupational cancer is another public health priority. Much has been already done in this area, even though some groups of workers are still experiencing increased cancer rates as a consequence of past exposures or of inadequate implementation of protective measures. It is unlikely that new major occupational risks will be discovered, that is, large cohorts of workers experiencing significantly increased cancer rates. Thus, the task of primary prevention in the area of occupational cancer is mainly to prevent new exposures to carcinogenic agents, either already known or new ones. The proportion of the overall cancer deaths which can be attributed to occupational exposure has not been established with certainty with various estimates ranging from 3% to more than 20% of all cancer deaths (9, 12). While 20% is likely to be an overestimate, one has to be reminded that type I1 error (due to lack ofstatistical power) is more ofa problem in many occupational studies than type I error, because of the limited size of many cohorts of workers and of the frequent misclassification of the exposure (20) . As a consequence, these estimates should be regarded as the minimal proportion of attributable cancers.
Other Agents. Other agents have been shown to increase cancer risk and include: iatrogenic factors, sexual and reproductive habits, infectious agents, polluting chemicals, and physical agents. While these may be particularly relevant to the etiology of a given cancer, or may strikingly increase cancer risk in a cohort of exposed individuals, their independent impact on the overall pattern ofcancer in Western countries is moderate.
CONCLUSIONS
It is unlikely that the overall pattern of cancer incidence and mortality in Western countries will show dramatic changes in the near future. A possible exception is the modification induced by a major decrease of the proportion of smokers in the general population which could result in preventing as many as 30% of deaths due to cancer. Incidence and mortality rates of most cancers not related to smoking are relatively stable, and it is unlikely that widespread exposures to strong carcinogens have recently occurred or can occur in the near future, in light of the screenings for carcinogenesis that are carried out on most new substances about to be introduced in the environment. The benefits resulting from the prevention of occupational exposures to carcinogens have probably not yet become manifest, but should not modify radically the overall pattern of cancer mortality. No public health measures are currently suggested (beside smoking control) or pursued, which might have a substantial impact on cancer incidence, while many efforts are devoted to studies in cancer detection and treatment. Early detection is unlikely to have any major role in cancer control, whereas therapy that in the future may prove to cure most patients with little side effects, is still pursuing more.modest goals and often failing to achieve them.
Thus, primary prevention must be critically reconsidered. In the past, public health choices were based too often on available human evidence only, with little cooperation between epidemiologists and oncologists. In recent years, epidemiologists have used knowledge derived from experimental studies of carcinogenesis in designing and interpreting their studies. In the future, hopefully, we will not have to wait until definite human evidence is available before taking any action, but we will consider all available knowledge, together with the potential risk and benefit of either acting or waiting for more evidence (8, 34).
The steady decrease in mortality from myocardial infarction observed in the U.S. in the last decade should tell us that hygienic advice can become acceptable, or even part of the lifestyle, modifying established habits in the population, with resulting
